LSV Asset Management Trims Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

LSV Asset Management lowered its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 23.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 1,089,300 shares of the company’s stock after selling 340,000 shares during the period. LSV Asset Management’s holdings in Amneal Pharmaceuticals were worth $6,612,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Rubric Capital Management LP boosted its position in Amneal Pharmaceuticals by 54.7% in the 3rd quarter. Rubric Capital Management LP now owns 4,024,500 shares of the company’s stock worth $16,983,000 after purchasing an additional 1,423,121 shares in the last quarter. Phocas Financial Corp. acquired a new stake in shares of Amneal Pharmaceuticals during the 4th quarter valued at about $4,339,000. Vanguard Group Inc. boosted its position in Amneal Pharmaceuticals by 3.1% during the third quarter. Vanguard Group Inc. now owns 13,548,300 shares of the company’s stock worth $57,174,000 after purchasing an additional 412,599 shares in the last quarter. Assenagon Asset Management S.A. increased its position in shares of Amneal Pharmaceuticals by 122.4% in the third quarter. Assenagon Asset Management S.A. now owns 515,233 shares of the company’s stock valued at $2,174,000 after buying an additional 283,524 shares in the last quarter. Finally, EAM Investors LLC acquired a new position in shares of Amneal Pharmaceuticals during the 3rd quarter worth approximately $972,000. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on AMRX shares. Piper Sandler upped their price objective on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an “overweight” rating in a research report on Thursday, March 21st. The Goldman Sachs Group lifted their price objective on Amneal Pharmaceuticals from $6.25 to $8.00 and gave the stock a “buy” rating in a report on Monday. StockNews.com downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, March 4th. Truist Financial reissued a “buy” rating and issued a $9.00 price objective (up from $7.00) on shares of Amneal Pharmaceuticals in a research note on Monday. Finally, Barclays upped their target price on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an “overweight” rating in a report on Monday, January 29th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $8.25.

Amneal Pharmaceuticals Trading Up 1.2 %

Shares of AMRX stock opened at $6.59 on Thursday. The company has a current ratio of 1.65, a quick ratio of 0.97 and a debt-to-equity ratio of 121.31. The company’s 50-day moving average price is $5.79 and its 200-day moving average price is $5.34. Amneal Pharmaceuticals, Inc. has a twelve month low of $1.74 and a twelve month high of $6.90. The stock has a market cap of $2.02 billion, a price-to-earnings ratio of -11.77 and a beta of 1.33.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its quarterly earnings data on Friday, March 1st. The company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of $0.05 by $0.07. The firm had revenue of $616.98 million for the quarter, compared to analysts’ expectations of $630.67 million. Amneal Pharmaceuticals had a positive return on equity of 234.06% and a negative net margin of 6.76%. As a group, equities analysts predict that Amneal Pharmaceuticals, Inc. will post 0.5 earnings per share for the current year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.